RESUMO
Cardiovascular disease has remained the top contributor to global mortality for decades, necessitating research into the most effective methods of its prevention and treatment. Simultaneous with an immense amount of discovery and innovation in the field of cardiology, certain therapies with traditional Chinese origins have become progressively more popular in the West in recent decades. Specifically, ancient meditative mind-body practices such as Qigong and Tai Chi may lower cardiovascular disease risk and severity through a focus on movement and meditation. Such practices are generally low-cost and modifiable, with few adverse effects. Studies have shown higher quality of life in patients with coronary artery disease and heart failure after participation in Tai Chi, as well as a positive impact on cardiovascular risk factors such as hypertension and waist circumference. Most studies in the field have various limitations, such as small sample size, lack of randomization, and inadequate control; however, these practices show potential as an adjunct in the prevention and treatment of cardiovascular disease. Patients unable or unwilling to partake in traditionally aerobic activities may benefit greatly from such mind-body therapies. Nonetheless, more studies are warranted for more definitive answers to the question of Tai Chi and Qigong's effectiveness. In this narrative review, we discuss the current evidence surrounding the effects of Qigong and Tai Chi on cardiovascular disease, in addition to the limitations and difficulties in conducting such studies.
RESUMO
Landiolol is an ultra-short-acting, highly cardio-selective, ß-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high ß1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other ß-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.
RESUMO
Artificial intelligence (AI) technology is poised to alter the flow of daily life, and in particular, medicine, where it may eventually complement the physician's work in diagnosing and treating disease. Despite the recent frenzy and uptick in AI research over the past decade, the integration of AI into medical practice is in its early stages. Cardiology stands to benefit due to its many diagnostic modalities and diverse treatments. AI methods have been applied to various domains within cardiology: imaging, electrocardiography, wearable devices, risk prediction, and disease classification. While many AI-based approaches have been developed that perform equal to or better than the state-of-the-art, few prospective randomized studies have evaluated their use. Furthermore, obstacles at the intersection of medicine and AI remain unsolved, including model understanding, bias, model evaluation, relevance and reproducibility, and legal and ethical dilemmas. We summarize recent and current applications of AI in cardiology, followed by a discussion of the aforementioned complications.
